Additional guidance to clinicians: Cannabis-based products for medicinal use

Document first published:
Page updated:
Publication type:

Following the Government’s announcement to reschedule certain cannabis-based products for medicinal use, NHS England has provided guidance to clinicians following the rescheduling which sets out our expectations of what this regulatory change will mean in practice for clinicians working in the NHS and in private practice in England.


This further letter has been issued which provides additional guidance to clinicians and organisations following the rescheduling of cannabis-based products for medicinal use. This clarifies the status of the clinical guidance issued, and provides further clarification in relation to synthetic cannabinoids for medicinal use.



A set of clinical frequently asked questions (FAQs) to provide further support to prescribers.